teva-erlotinib tablet
teva canada limited - erlotinib (erlotinib hydrochloride) - tablet - 150mg - erlotinib (erlotinib hydrochloride) 150mg - antineoplastic agents
esomeprazole teva pharma 20 milligram tablets gastro-resistant
teva pharma b.v. - esomeprazole - tablets gastro-resistant - 20 milligram - proton pump inhibitors
esomeprazole teva pharma 40 milligram tablets gastro-resistant
teva pharma b.v. - esomeprazole - tablets gastro-resistant - 40 milligram - proton pump inhibitors
omeprazole teva pharma 10 mg gastro-resistant capsules, hard
teva pharma b.v. - omeprazole - gastro-resistant capsule - 10 milligram(s) - proton pump inhibitors; omeprazole
omeprazole teva pharma 20 mg gastro-resistant capsules, hard
teva pharma b.v. - omeprazole - gastro-resistant capsule - 20 milligram(s) - proton pump inhibitors; omeprazole
omeprazole teva pharma 40 mg gastro-resistant capsules, hard
teva pharma b.v. - omeprazole - gastro-resistant capsule, hard - 40 milligram(s) - proton pump inhibitors; omeprazole
pantoprazole teva pharma 20 mg gastro-resistant tablets
teva pharma b.v. - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 20 milligram(s) - proton pump inhibitors; pantoprazole
pantoprazole teva pharma 40 mg gastro-resistant tablets
teva pharma b.v. - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40 milligram(s) - proton pump inhibitors; pantoprazole
erlotinib taro 100 mg
taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 100 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
erlotinib taro 150 mg
taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 150 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.